About Acorda
Acorda is a company based in Ardsley (United States) founded in 1995 was acquired by Merz in May 2024. Acorda has raised $66.5 million across 3 funding rounds from investors including J P Morgan, ABN AMRO and Easton Capital Investment Group. The company has 109 employees as of December 31, 2022. Acorda has completed 3 acquisitions, including Biotie, Civitas Therapeutics and Neuronex. Acorda offers products and services including AMPYRA, INBRIJA, and ARCUS Technology. Acorda operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
- Headquarter Ardsley, United States
- Employees 109 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Acorda Therapeutics Inc.
-
Annual Revenue
$118.57 M (USD)-8as on Dec 31, 2022
-
Net Profit
-$65.92 M (USD)37as on Dec 31, 2022
-
EBITDA
-$35.34 M (USD)55as on Dec 31, 2022
-
Total Equity Funding
$66.5 M (USD)
in 3 rounds
-
Latest Funding Round
$31.5 M (USD), Post-IPO
Oct 01, 2006
-
Investors
J P Morgan
& 4 more
-
Employee Count
109
as on Dec 31, 2022
-
Investments & Acquisitions
Biotie
& 2 more
-
Acquired by
Merz
(May 15, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Acorda
Acorda offers a comprehensive portfolio of products and services, including AMPYRA, INBRIJA, and ARCUS Technology.
Drug for improving walking in multiple sclerosis patients.
Inhalation powder for managing Parkinson's disease symptoms.
Technology platform for neurological drug delivery systems.
People of Acorda
Unlock access to complete
Unlock access to complete
Funding Insights of Acorda
Acorda has successfully raised a total of $66.5M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $31.5 million completed in October 2006. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Acorda
Acorda has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include J P Morgan, ABN AMRO and Easton Capital Investment Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Capital is invested in life science innovations for healthcare transformation.
|
Locked | Locked | Locked | |
|
ABN AMRO is recognized as a personal bank in the digital era.
|
Locked | Locked | Locked |
Investor details for Acorda
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Acorda
Acorda has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Biotie, Civitas Therapeutics and Neuronex.
Investment portfolio details for Acorda
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Nasal spray formulation of diazepam is developed for seizure disorders.
|
Locked | Locked | 2010 | Locked | |
|
Inhaled pulmonary therapies for Parkinson's motor fluctuations are developed.
|
Locked | Locked | 2009 | Locked | |
|
Drugs for neurodegenerative and psychiatric disorders are developed by Biotie.
|
Locked | Locked | 1998 | Locked |
Complete acquisition details for Acorda
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Acorda
Detailed financials for Acorda
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Acorda Comparisons
Peer comparison for Acorda
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Acorda
Acorda operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| Locked | Locked | Locked |
Gene and protein therapies are developed for treating various diseases.
|
Detailed competitors of Acorda
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Acorda
Complete news archive for Acorda
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Acorda
Acorda was founded in 1995 and raised its 1st funding round 8 years after it was founded.
Acorda is headquartered in Ardsley, United States. It is registered at Ardsley, New York, United States.
Acorda is a funded company, having raised a total of $66.5M across 3 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Acorda is 109.
Annual revenue of Acorda is $118.57M as on Dec 31, 2022.
Acorda Therapeutics was founded in 1995 as a biopharmaceutical company focused on the identification, development, and commercialization of treatments for neurological conditions, including multiple sclerosis and spinal cord injury. Operations center on products such as Ampyra, approved in 2010 for improving walking in MS patients, and Zanaflex Capsules for spasticity management. The company is headquartered in Ardsley, United States, within the healthcare sector.
Acorda's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
Acorda offers AMPYRA, INBRIJA, and ARCUS Technology.
Acorda has made 3 acquisitions, including Biotie, Civitas Therapeutics, and Neuronex.
Acorda has 5 investors. Key investors include J P Morgan, ABN AMRO, Easton Capital Investment Group, TVM Capital Life Science, and Merz Therapeutics.